Evidence map›Paper›PMID 40829965›Full record

ArticleThe Lancet. Digital health2025

Assessing genotype-phenotype correlations in colorectal cancer with deep learning: a multicentre cohort study.

Marco Gustav, Marko van Treeck, Nic G Reitsam, Zunamys I Carrero, Chiara M L Loeffler, Asier Rabasco Meneghetti, Bruno Märkl, Lisa A Boardman, Amy J French, Ellen L Goode and 12 more

Abstract readMulticenter Study
In one paragraph

Article in The Lancet. Digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Marco GustavElse Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
Marko van TreeckElse Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
Nic G ReitsamPathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Zunamys I CarreroElse Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
Chiara M L LoefflerElse Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany; Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
Asier Rabasco MeneghettiElse Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
Bruno MärklPathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Lisa A BoardmanDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Amy J FrenchDivision of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Ellen L GoodeDepartment of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
Andrea GsurCenter for Cancer Research, Medical University of Vienna, Vienna, Austria.
Stefanie BrezinaCenter for Cancer Research, Medical University of Vienna, Vienna, Austria.
Marc J GunterNutrition and Metabolism Branch, International Agency for Research on Cancer, WHO, Lyon, France; Cancer Epidemiology and Prevention Research Unit, School of Public Health, Imperial College London, London, UK.
Neil MurphyNutrition and Metabolism Branch, International Agency for Research on Cancer, WHO, Lyon, France.
Pia HönscheidInstitute of Pathology, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany; National Center for Tumor Diseases, Partner Site Dresden, German Cancer Research Center Heidelberg, Dresden, Germany; German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany.
Christian SperlingInstitute of Pathology, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
Sebastian FoerschInstitute of Pathology, University Medical Center Mainz, Mainz, Germany.
Robert SteinfelderDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Tabitha HarrisonDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Ulrike PetersDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Amanda PhippsDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Jakob Nikolas KatherElse Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany; Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany; Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Pathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK. Electronic address: jakob-nikolas.kather@alumni.dkfz.de.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
NCI NIH HHS P30 CA015083World Health Organization 001
6 · The paper itself

Abstract

backgroundDeep learning-based models enable the prediction of molecular biomarkers from histopathology slides of colorectal cancer stained with haematoxylin and eosin; however, few studies have assessed prediction targets beyond microsatellite instability (MSI), BRAF, and KRAS systematically. We aimed to develop and validate a multi-target model based on deep learning for the simultaneous prediction of numerous genetic alterations and their associated phenotypes in colorectal cancer.

methodsIn this multicentre cohort study, tissue samples from patients with colorectal cancer were obtained by surgical resection and stained with haematoxylin and eosin. These samples were then digitised into whole-slide images and used to train and test a transformer-based deep learning algorithm for biomarker detection to simultaneously predict multiple genetic alterations and provide heatmap explanations. The primary dataset comprised 1376 patients from five cohorts who underwent comprehensive panel sequencing, with an additional 536 patients from two public datasets for validation. We compared the model's performance against conventional single-target models and examined the co-occurrence of alterations and shared morphology.

findingsThe multi-target model was able to predict numerous biomarkers from pathology slides, matching and partly exceeding single-target transformers. In the primary external validation cohorts, mean area under the receiver operating characteristic curve (AUROC) for the multi-target transformer was 0·78 (SD 0·01) for BRAF, 0·88 (0·01) for hypermutation, 0·93 (0·01) for MSI, and 0·86 (0·01) for RNF43; predictive performance was consistent across metrics and supported by co-occurrence analyses. However, biomarkers with high AUROCs largely correlated with MSI, with model predictions depending considerably on morphology associated with MSI at pathological examination.

interpretationBy use of morphology associated with MSI and more subtle biomarker-specific patterns within a shared phenotype, the multi-target transformers efficiently predicted biomarker status for diverse genetic alterations in colorectal cancer from slides stained with haematoxylin and eosin. These results highlight the importance of considering mutational co-occurrence and common morphology in biomarker research based on deep learning. Our validated and scalable model could support extension to other cancers and large, diverse cohorts, potentially facilitating cost-effective pre-screening and streamlined diagnostics in precision oncology.

fundingGerman Federal Ministry of Health, Max-Eder-Programme of German Cancer Aid, German Federal Ministry of Education and Research, German Academic Exchange Service, and the EU.

Indexed as

Colorectal NeoplasmsDeep LearningGenetic Association StudiesAgedBiomarkers, TumorCohort StudiesFemaleHumansMaleMicrosatellite InstabilityMiddle AgedPhenotypeProto-Oncogene Proteins B-rafBiomarkers, TumorBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID40829965
PMCPMC13274733

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.